Built on science. Run by operators.

Molecular biology from Sorbonne and CNRS meets storage-industry execution from Hitachi and Hitachi Vantara.

Origin

Biomemory spun out of Sorbonne University and CNRS in 2021

Biomemory spun out of Sorbonne University and CNRS in 2021. Most players in DNA data storage hold one piece of the stack; Biomemory spans molecular biology, biochemistry, hardware, software, and industrial production in a single integrated platform, the hard part of this field. The same research lineage reached a sovereign milestone in 2021, when the French National Archives preserved two founding texts in DNA using the CNRS and Sorbonne science behind Biomemory.

The decision since has been to industrialize that science rather than keep it in the laboratory. After the Catalog assets acquisition, Biomemory owns DNA production in Boston alongside its site in Paris. As of 7th September 2026, pending final country-level reconciliation. Biomemory's IP portfolio spans 21 patent families, with 53 patents already granted — across 10 of those families — and 84 further applications pending, for 137 total filings worldwide spanning encoding, synthesis, storage, retrieval, search, and compute.

Governance

Built by scientists and operators

Laurent Guengant

CEO

Storage, telecom and energy executive with 30+ years leading global businesses, strategy, growth and transformation.

Erfane Arwani

Co-founder & Executive Chairman

Founder and entrepreneur with 10+ years building cloud and storage companies from vision to scale

Vincent Franceschini

Head of Product

Storage industry veteran with 30+ years spanning research, product leadership and innovation at global companies

Dominique Loque

Chief Scientific Officer

Molecular biology executive with 20+ years advancing life sciences, biotechnology and scientific innovation across industries

Jessica Ayache

Head of Biotech

Biotechnology leader with 10+ years in biology and biochemistry, combining scientific expertise with industrial execution

Frédéric Larriere

Chief Financial Officer

Finance and strategy leader with 26 years spanning high-growth, LBOs, turnarounds, fundraising and financial operations.

Cyril Martin

Head of Hardware

Hardware and systems leader with 20+ years delivering complex products at Apple, Microsoft and startups

Ellen Simmons

Boston Lead Engineer

12 yrs XP in Biosystems 1st person in the world to build a DNA data storage printer

Biomemory DNA data storage system in the lab

Production

Biomemory DNA production

After Catalog’s assets acquisition in 2026, Biomemory owns DNA production in Boston, with a second line to come in Paris. With patents spanning encoding, synthesis, storage, retrieval, search, and compute, and co-chairmanship of the DNA Data Storage Alliance.

It is common knowledge that it will be possible to read DNA for centuries to come. Biomemory codecs efficiently encode DNA for fast reading through our software.

Standards

SNIA DNA Data Storage Alliance

Biomemory is a leader in commercial DNA data storage and is a member of the DNA Data Storage Alliance, a SNIA Community. Biomemory's representative Vincent Franceschini is the current co-chair of the DDSA, and Chairman Emeritus of SNIA.

Our story

Beyond silicon

2021 - From research to reality

Biomemory spins out of CNRS and Sorbonne University, building on years of academic research. Its technology is demonstrated through a landmark project: storing the French Declaration of the Rights of Man and of the Citizen and the Declaration of the Rights of Woman in DNA, with copies preserved by the French National Archives.

2024 - €18M to turn technology into products

Biomemory raises €18 million from Bpifrance, Crédit Mutuel Innovation, Blast and other investors. The funding accelerates technology development and, critically, its productization, turning scientific breakthroughs into deployable DNA Data Storage solutions and enabling the company to engage its first customers.

March 2026 - Scaling up with Catalog’s technology and expertise

Biomemory acquires key assets from Catalog, significantly expanding its capabilities and intellectual property portfolio to more than 90 patents. The acquisition also brings world-class DNA Data Storage experts into the team and establishes a production and R&D footprint in Boston, alongside its Paris operations.

June 2026 - Opening a new route to enterprise customers

Biomemory signs its first partnership with a cloud and data storage provider, Scality. The collaboration creates an additional route into enterprise IT environments, complementing Biomemory’s direct sales model and paving the way for DNA Data Storage to integrate with existing storage infrastructures.

October 2026 - DNA Shield launch

Biomemory launches the world's first DNA data storage service with DNA Shield. DNA Shield is a managed service for sovereign data protection. It is designed to hold small, irreplaceable data offline, in-jurisdiction, and separated from the systems it protects.

Biomemory awarded

LinkedIn Top Startups 2026

Locations

Europe and North America

Paris

Headquarters and DNA research

5 impasse Reille, 75014 Paris, France

Boston

DNA production and research

529 Main Street, Suite 125 (AKA 1025), Charlestown, MA 02129 USA

Investors enquiries

The Opportunity

Data is growing faster than the media built to hold it, and the data that matters most is the hardest to keep safe.

DNA is a new layer in the IT stack, beyond silicon: enormous capacity in almost no space, held for decades, with no power at rest and no network for an attacker to reach.

DNA takes share of large, established markets: cold storage, enterprise archiving, and data security. Together these are worth tens of billions of dollars today and head toward the hundreds of billions within a decade.

The DNA category inside them is early and growing fast, with serious capital and several players moving in.

Biomemory's near-term focus is the security and archive segments.

Storage is the first market. Molecular computing is the next.